tradmap

FDMT 4d Molecular Therapeutics, Inc.

$9.64 +2.28%

Healthcare · Biological Products, (No Diagnostic Substances)

4d Molecular Therapeutics, Inc. (FDMT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $504 million. Shares last traded at $9.64, 21.9% below their 52-week high. Over the past year the stock is up 133.0%. Net profit margin is -164.4%, below the peer median of 6.3%. Revenue grew 230194.6% year over year.

Market Cap
$504M
Shares Out
52.3M
EPS (TTM)
$-6.56
P/E Ratio
P/S Ratio
5.92
P/B Ratio
1.12
Dividend / Share
Dividend Yield
52-Week High
$12.35
52-Week Low
$3.66
Volume
25,433
Avg Vol (3m)
38,315.063

Performance

1W
+8.98%
1M
+14.68%
3M
+7.29%
6M
-16.28%
YTD
+31.67%
1Y
+132.97%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
54.33
SMA (50)
$9.43
SMA (200)
$9.24
Price vs SMA50
+2.24%
Price vs SMA200
+4.38%
ATR (14)
$0.70

Financials

Revenue
$85M
Net Income
$-140M
Gross Margin
Operating Margin
-187.2%
Net Margin
-164.4%
Return on Equity
-31.0%
Return on Assets
-27.3%
Current Ratio
9.34
Debt / Equity
0.14
Revenue Growth (YoY)
+230194.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-1.01 2026-05-07
FY 2025 $-2.42 2026-03-18
Q3 2025 $-2.85 2025-11-10
Q2 2025 $-1.84 2025-08-11
Q1 2026 $-0.86 2026-05-07
FY 2025 $-2.98 2026-03-18

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

FDMT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
5.92 / 5.21 med
+13% premium
Net margin vs peers
-164.4% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.